Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tourmaline Bio, Inc. - Common Stock (NQ:TRML)

23.59 +0.19 (+0.81%)
Streaming Delayed Price Updated: 3:07 PM EDT, Sep 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 94,449
Open 23.26
Bid (Size) 23.58 (1)
Ask (Size) 23.65 (1)
Prev. Close 23.40
Today's Range 23.05 - 24.08
52wk Range 11.56 - 29.79
Shares Outstanding 42,166,025
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Reports Loss as R&D Rises
Via The Motley Fool

Performance

YTD
+14.3%
+14.3%
1 Month
+9.3%
+9.3%
3 Month
+37.9%
+37.9%
6 Month
+91.3%
+91.3%
1 Year
+46.7%
+46.7%

More News

Read More
Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill
Trip.com Posts Weak Earnings, Joins Vipshop, Viking Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
What's going on in today's pre-market session
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
This Tourmaline Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Via Benzinga
Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025
From Tourmaline Bio, Inc.
Via GlobeNewswire
This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Present at Upcoming Investor Conferences
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
From Tourmaline Bio, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Tourmaline Bio, Inc. - Common Stock publicly traded?
Yes, Tourmaline Bio, Inc. - Common Stock is publicly traded.
What exchange does Tourmaline Bio, Inc. - Common Stock trade on?
Tourmaline Bio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Tourmaline Bio, Inc. - Common Stock?
The ticker symbol for Tourmaline Bio, Inc. - Common Stock is TRML on the Nasdaq Stock Market
What is the current price of Tourmaline Bio, Inc. - Common Stock?
The current price of Tourmaline Bio, Inc. - Common Stock is 23.59
When was Tourmaline Bio, Inc. - Common Stock last traded?
The last trade of Tourmaline Bio, Inc. - Common Stock was at 09/02/25 03:07 PM ET
What is the market capitalization of Tourmaline Bio, Inc. - Common Stock?
The market capitalization of Tourmaline Bio, Inc. - Common Stock is 994.70M
How many shares of Tourmaline Bio, Inc. - Common Stock are outstanding?
Tourmaline Bio, Inc. - Common Stock has 995M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.